DDInter1388 DDInter1822
Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).[L32739, L32744, L32749]
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Pantoprazole {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Tobramycin
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Paromomycin
Paromomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neomycin
Neomycin {u} (Compound) resembles {v} (Compound) Paromomycin
Paromomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Pantoprazole {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) resembles {v} (Compound) Tobramycin
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neomycin
Neomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neomycin
Neomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) resembles {v} (Compound) Tobramycin
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Pantoprazole (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Tobramycin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) resembles Tobramycin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) resembles Kanamycin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) resembles Tobramycin (Compound)
Pantoprazole (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Kanamycin (Compound) and Kanamycin (Compound) resembles Tobramycin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Gentamicin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) resembles Tobramycin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin (Compound) resembles Tobramycin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) resembles Tobramycin (Compound)